Nuvalent
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 92
- Market Cap
- $5.4B
- Website
- http://www.nuvalent.com
- Introduction
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
- Conditions
- Non Small Cell Lung CancerALK-positive Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Nuvalent Inc.
- Registration Number
- NCT06834074
- Locations
- 🇺🇸
Henry Ford Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
- Conditions
- Non Small Cell Lung CancerROS1-positive Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Nuvalent Inc.
- Registration Number
- NCT06797362
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇮🇹L'Istituto Europeo di Oncologia S.r.l., Milan, Italy
🇮🇹AUSL della Romagna - Ravenna, Ravenna, Italy
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Conditions
- Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
- Interventions
- Drug: Neladalkib (NVL-655)
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06765109
- Locations
- 🇺🇸
University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
🇬🇧Cambridge University Hospitals NHS Trust, Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧Guy's Cancer Centre NHS Foundation Trust, London, United Kingdom
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06521554
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Princess Margaret Cancer Center - University Health Network, Toronto, Ontario, Canada
🇺🇸City of Hope - Lennar, Irvine, California, United States
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- Drug: Neladalkib (NVL-655)
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 840
- Registration Number
- NCT05384626
- Locations
- 🇺🇸
University of California Irvine Medical Center, Orange, California, United States
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
- Prev
- 1
- 2
- Next